onvitrelin ucalontide (AT-101) / A28 Therap - LARVOL DELTA

A28 Therapeutics and GATC Health Announce Comprehensive AI-Powered Analysis, Predicting Efficacy, Safety, and Potential Off-Target Effects of A28’s AT-101 Cancer Drug Candidate (PRNewswire) - "A28 Therapeutics, Inc...today announced during the J.P. Morgan Healthcare Conference the completion of a comprehensive activity analysis for its AT-101 cancer drug candidate. This AI analysis by GATC Health Corp...not only validates the potential of AT-101 but also provides A28 Therapeutics with a powerful tool to optimize its clinical trial strategy....GATC's Multiomics Advanced Technology (MAT) AI platform performed in-silico experiments to determine the safety, efficacy and side-effect profile for A28's asset."

Preclinical • Oncology

Simultaneous determination of phenols in the four main original plants of the famous traditional Chinese medicine Shihu by pressurized capillary electrochromatography. (PubMed, RSC Adv) - "The investigated 11 phenols could be isolated in 35 min on a reversed-phase EP-100-20/45-3-C18 capillary column using the established method...These further suggested that the components of the four original plants of TCM Shihu might be significantly different. Further investigation should be conducted to confirm and evaluate if the four species could be used as the same medicine with the same amount according to Chinese Pharmacopoeia (ChP)."

Journal

Simultaneous determination of 16 important biologically active phytohormones in Dendrobium huoshanese by pressurized capillary electrochromatography. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The results showed that the 16 phytohormones could be baseline-separated rapidly in less than 21 min on a reversed-phase EP-100-20/45-3-C18 capillary column (total length of 45 cm, effective length of 20 cm, diameter of 100 μm, ODS packing inside for 3 μm) with ACN/5.0 mM ammonium acetate (containing 0.05% formic acid, pH = 3) as the mobile phase using gradient elution mode as follows: 0.1-10.0 min 40%ACN,10-15.0 min 70%ACN, 15.0-20 min 80% ACN, 20-21.0 min 80% ACN at a flow rate of 0.12 mL/min, applied voltage of -5 kV and a UV detection wavelength of 210 nm...Employed the established method, in our experimental conditions, total 6 endogenous hormones including IAA, IBA, NAA, GA, ABA, t-Z were detected in D. huoshense. However, a relative larger amount of exogenous hormone 2,4-D (25.3 ~ 4.2 μg/kg) and 6-BA (79.5 ~ 35.4 μg/kg) were detected in 1 ~ 4 year old..."

Journal • Transplantation

EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor (AACR 2018) - "We first examined the cytotoxic effects of EP-100 alone on 8 ovarian cancer cell lines with variable expression level of LHRH receptors and the IC50 values ranged from 0.5 to 2.0 M. We then tested the effect of combining EP-100 with standard drugs (e.g., cisplatin, paclitaxel, doxorubicin, topotecan, and olaparib) on ovarian cancer cells. EP-100 has efficacy in preclinical models of ovarian cancer, especially in combination with olaparib. Our findings suggested that combining EP-100 with olaparib could be a promising therapeutic strategy for ovarian cancer."

BRCA Biomarker • IO biomarker • PARP Biomarker • Ovarian Cancer

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer. (PubMed, Gynecol Oncol) - "ORR in the EP-100 combination arm was similar to that in the group treated with paclitaxel alone; however, a subset of patients with liver metastases appeared to benefit from the combination. The addition of EP-100 did not appear to augment the adverse event profile of paclitaxel and was well tolerated."

Clinical • Journal • P2 data • Liver Cancer • Oncology • Ovarian Cancer • Solid Tumor

Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer. (PubMed, Mol Cancer Ther) - "These results warrant further clinical development of this combination. Keywords: EP-100, LHRH-R, PD-L1 antibody, Ovarian cancer."

Journal • Immune Modulation • Inflammation • Oncology • Ovarian Cancer • Solid Tumor • CD8 • VEGFA

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. (PubMed) - Nat Commun - "The Arf6-based pathway may also contribute to drug resistance. Our results identify a specific mesenchymal molecular machinery of primary ccRCCs, which is triggered by a product of autotaxin and it is associated with poor outcome of patients."

Journal • Biosimilar • Breast Cancer • Oncology • Renal Cell Carcinoma • Triple Negative Breast Cancer

Macula in Early Glaucoma: Study by OCT Angiography and Electrophysiological Testing (APAO 2017) - "...The electrophysiological study was done using Tomey EP-1000... The present study revealed the significance of OCT-A for the early diagnosis of glaucoma and the importance of investigating macular microcirculation. The combination of OCT-A and pattern ERG and VEP provide perspective in the early detection of glaucoma."

Clinical • Biosimilar • Glaucoma • Ophthalmology

GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition. (PubMed, Mol Cancer Ther) - "Of five standard drugs tested (cisplatin, paclitaxel, doxorubicin, topotecan, and olaparib), we found that the combination of EP-100 and olaparib was synergistic in ovarian cancer cell lines. In vivo experiment using the HeyA8 mouse model demonstrated that mice treated with EP-100 and olaparib had lower tumor weights (0.06 ± 0.13 g) than those treated with a vehicle (1.19 ± 1.09 g), EP-100 alone (0.62 ± 0.78 g), or olaparib alone (0.50 ± 0.63 g). Our findings indicate that combining EP-100 with olaparib is a promising therapeutic strategy for ovarian cancer."

Journal

Targeting LHRH-R to improve immune response in ovarian cancer (AACR 2019) - "These data demonstrate strong efficacy of EP-100 and checkpoint blockade therapy. Our results provide new directions to enhance the efficacy of immune therapies for ovarian cancer."